Join our daily newsletter At The Bell to receive exclusive market insights
- Neurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effective from Tuesday, next week
- Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments
- She has a Doctor of Philosophy in Neuroscience from the University of Western Australia
- Dr Andrews will be paid a base salary of $250,000 inclusive of superannuation and will receive 15 million options, exercisable at different prices
- Shares are trading flat today at 4.5 cents each
Neurotech International (NTI) has appointed Alexandra Andrews as Chief Executive Officer (CEO), effective from Tuesday, next week.
Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.
She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.
Dr Andrews will be paid a base salary of $250,000 inclusive of superannuation.
In addition, she will receive 15 million unlisted options exercisable at 8 cents, 12 cents, and 16 cents, provided she remains employed by the company as CEO.
Previously, she was Director of Operations at NeuroScientific Biopharmaceuticals.
Her career has seen her work with clinical researchers, investors, and entrepreneurs, where she has overseen manufacturing and provided input into clinical development plans.
At Linear Clinical Research, she secured partnerships with US biotechnology and pharmaceutical companies and managed trial logistics.
Dr Andrews said she is excited to be joining the company as CEO.
“I am delighted to be joining Neurotech International as CEO at this exciting time as clinical research into Neurotech’s low level THC cannabis plant strains is unfolding – initially in children with Autism, then in other neurological and inflammatory disorders,” she said.
“I am passionate about improving patient outcomes and am looking forward to collaborating with the team in leveraging NTI’s novel technology to accelerate advancements in health and medicine.”
Shares were trading flat today at 4.5 cents each at 1.58 pm AEDT.
